Curcumin enhances dasatinib‐induced inhibition of growth and transformation of colon cancer cells
Open Access
- 22 December 2010
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 128 (4), 951-961
- https://doi.org/10.1002/ijc.25410
Abstract
Colorectal cancer is the third most common form of malignancy, behind prostate and lung cancers. Despite recent advances in medicine, mortality from colorectal cancer remains high, highlighting the need for improved therapies. Numerous studies have demonstrated increased activation of EGFR and its family members (EGFRs), IGF‐1R as well as c‐Src in colorectal cancer. The current study was undertaken to examine the effectiveness of combination therapy of dasatinib (BMS‐354825; Bristol‐Myers Squibb), a highly specific inhibitor of Src family kinases (SFK) and a nontoxic dietary agent; curcumin (diferuloylmethane), in colorectal cancer in in vitro and in vivo experimental models. For the latter, we utilized C57BL/6 APCMin+/− mice. Initial in vitro studies revealed synergistic interactions between the two agents. Additionally, we have observed that combination treatment causes a much greater inhibition of the following metastatic processes than either agent alone: (i) colony formation, (ii) invasion through extracellular matrix and (iii) tubule formation by endothelial cells. Dasatinib affects the cell adhesion phenotype of colon cancer HCT‐116 cells whereas the combination therapy enhances this effect to a greater extent. Preclinical investigation revealed that the combination therapy to be highly effective causing an over 95% regression of intestinal adenomas in ApcMin+/− mice, which could be attributed to decreased proliferation and increased apoptosis. In conclusion, our data suggest that combination treatment of dasatinib and curcumin could be a potential therapeutic strategy for colorectal cancer.Keywords
This publication has 57 references indexed in Scilit:
- Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteinsCancer Letters, 2008
- Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasionMolecular Cancer Therapeutics, 2007
- Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for SurvivalCancer Research, 2007
- Multiple biological activities of curcumin: A short reviewLife Sciences, 2006
- Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer CellsClinical Cancer Research, 2005
- RIα influences cellular proliferation in cancer cells by transporting RFC40 into the nucleusCancer Biology & Therapy, 2005
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirinGastroenterology, 1998
- Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L.CHEMICAL & PHARMACEUTICAL BULLETIN, 1985